While some might interpret such studies to indicate that some subsets of patients with FLT3-ITD-mutated AML (defined by NPM1 mutation status and low allelic ratio) should receive consolidation chemotherapy in preference to alloHSCT, the lack of a standard method of determining the allelic ratio makes this problematic. This evidence concerns the gene FLT3 and acute myeloid leukemia.